David Penson

Vanderbilt University Medical Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (3)

Daniel Barocas

Professor and Executive Vice Chair

Vanderbilt University Medical Center

UNITED STATES

View details

Christopher J.D. Wallis

CANADA

View details

Bashir Al Hussein Al Awamlh

Cornell University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

David Penson

Research Interests

Explore related searches

Contact this professor

Articles (10)

Projected Savings for Generic Oncology Drugs Purchased via Mark Cuban Cost Plus Drug Company Versus in Medicare

Point-Counterpoint: Clinical Pragmatism Should Prevail Over Biological Orthodoxy: “Pro” Perspective

Correction to: Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer

Correction to: Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer

Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer

Prostate volume, baseline urinary function, and their association with treatment choice and post-treatment urinary function in men treated for localized prostate cancer

Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial

Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial

Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region

Out-of-pocket costs for commercially insured patients with localized prostate cancer

Collaborators (3)

Daniel Barocas

Christopher J.D. Wallis

Bashir Al Hussein Al Awamlh

Make your next move.